**5. Summary**

A new method of electrophoretic lipoprotein separation on polyacrylamide gel (PAG)using the Lipoprint LDL System can quantify non-atherogenic and atherogenic plasma lipoproteins, including small dense LDL, i.e. strong atherogenic lipoprotein subpopulations.

With respect to the predominance of a non-atherogenic or atherogenic lipoproteins in thewhole lipoprotein profile, this method distinguishes a non-atherogenic lipoprotein profilephenotype A from an atherogenic lipoprotein profile phenotype B.

The contribution of this method is to confirm the existence of a non-atherogenic type of hyper-betalipoproteinaemia and the existence of normolipidemia with atherogenic lipoprotein profile, along with the common and well-known atherogenic hyperlipoproteinemia and non-atherogenic normolipidemia.

According to our preliminary analysis of a normolipidemic population, an atherogenic lipoprotein profile was revealed in 6% of normolipidemic young healthy individuals.

More than 40% of the examined individuals in the general group of subjects had an atherogenic lipoprotein profile phenotype B. These people represent an at-risk population.

However, the tools by which is possible to identify these individuals at risk for a cardiovascular event are limited.

A non-atherogenic hyperbetalipoproteinemiaLDL1,2 can be identified, which represents approxmately 20% of examined individuals with hypercholesterolemia and 10% of individuals in a general group of subjects. HyperbetalipoproteinemiaLDL1,2 is not associated with the premature development of arterial vascular impairment.
